NCT05552976 2026-03-17
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT06615479 2026-03-17
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07221253 2026-03-17
AB02
AstraZeneca
Phase 3 Recruiting
NCT05519085 2026-03-11
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT06149286 2026-03-06
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06551324 2026-03-04
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT07166094 2026-03-03
RAINFOL-03
Genmab
Phase 3 Recruiting
NCT06760637 2026-03-02
FourLight-3
Pfizer
Phase 3 Recruiting
NCT07138209 2026-02-27
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting